9953330565 Low Rate Call Girls In Rohini Delhi NCR
Bipolar TherapyBipolar TherapyClient of Korean DescentAncestr.docx
1. // Bipolar TherapyBipolar Therapy
Client of Korean Descent/Ancestry
BACKGROUND INFORMATION
The client is a 26-year-old woman of Korean descent who
presents to her first appointment following a 21-day
hospitalization for onset of acute mania. She was diagnosed
with bipolar I disorder.
Upon arrival in your office, she is quite “busy,” playing with
things on your desk and shifting from side to side in her chair.
She informs you that “they said I was bipolar, I don’t believe
that, do you? I just like to talk, and dance, and sing. Did I tell
you that I liked to cook?”
She weights 110 lbs. and is 5’ 5”
SUBJECTIVE
Patient reports “fantastic” mood. Reports that she sleeps about 5
hours/night to which she adds “I hate sleep, it’s no fun.”
You reviewed her hospital records and find that she has been
medically worked up by a physician who reported her to be in
overall good health. Lab studies were all within normal limits.
You find that the patient had genetic testing in the hospital
(specifically GeneSight testing) as none of the medications that
they were treating her with seemed to work.
Genetic testing reveals that she is positive for CYP2D6*10
allele.
Patient confesses that she stopped taking her lithium (which was
prescribed in the hospital) since she was discharged two weeks
ago.
MENTAL STATUS EXAM
The patient is alert, oriented to person, place, time, and event.
She is dressed quite oddly- wearing what appears to be an
evening gown to her appointment. Speech is rapid, pressured,
tangential. Self-reported mood is euthymic. Affect broad.
Patient denies visual or auditory hallucinations, no overt
delusional or paranoid thought processes readily apparent.
2. Judgment is grossly intact, but insight is clearly impaired. She
is currently denying suicidal or homicidal ideation.
The Young Mania Rating Scale (YMRS) score is 22
RESOURCES
§ Chen, R., Wang, H., Shi, J., Shen, K., & Hu, P. (2015).
Cytochrome P450 2D6 genotype affects the pharmacokinetics of
controlled-release paroxetine in healthy Chinese subjects:
comparison of traditional phenotype and activity score systems.
European Journal of Clinical Pharmacology, 71(7), 835-841.
doi:10.1007/s00228-015-1855-6
Decision Point OneSelect what the PMHNP should do:Begin
Lithium 300 mg orally BID
Begin Risperdal 1 mg orally BID
Begin Seroquel XR 100 mg orally at HS
36. Observe legal requirements for dispensing patient data
Use caution with fax machines, e-mail, and other electronic
devices
Provide only facts
Always be nonjudgmental
Confirm receipt of message
Back to Learning Outcomes
// Bipolar TherapyBipolar Therapy
Client of Korean Descent/Ancestry
Decision Point One
Begin Lithium 300 mg orally BID
RESULTS OF DECISION POINT ONE Client returns to clinic
37. in four weeks Client informs the PMHNP that she has been
taking her drug “off and on” only when she “feels like she
needs it” Today’s presentation is similar to the first day you
met her
Decision Point Two
Select what the PMHNP should
do next:Increase Lithium to 450 mg orally BID
RESULTS OF DECISION POINT TWO Client returns to clinic
in four weeks Client returns reports that she is still taking the
medication when she feels that she needs it She remains quite
manic and reports that her family is getting really upset because
she likes to play her new guitar at night
Decision Point Three
Select what the PMHNP should
do next:Assess for rationale for non-compliance and educate
38. client
Guidance to Student
The PMHNP should further assess for
dangerousness to self or others. The client should be assessed
for self-care, to including hygiene, eating, sleeping, etc.
Hospitalization may be indicated if the client remains non-
compliant and is a danger to self. If the client is not a danger to
self, and hospitalization is not indicated, the PMHNP needs to
assess for rationale for non-compliance. Many clients enjoy
mania as it is a nice feeling to be consistently happy. When
clients are successfully treated for mania, they often describe
themselves as feeling ‘down’ or ‘flat.’ The PMHNP needs to
assess for depression at this point as opposed to normalization
of mood. Abilify is also FDA approved as monotherapy for
mania and mixed presentations, but at a dose of 15 mg. day., so
although you may be tempted to begin Abilify- be certain to use
correct dose. Also, because it can be “activating” you need to
dose this drug in the morning. However, the client is non-
compliant and therefore, eliciting reasons for non-compliance is
essential to the care of this client.
Start OverConsider hospitalization
Guidance to Student
The PMHNP should further assess for
39. dangerousness to self or others. The client should be assessed
for self-care, to including hygiene, eating, sleeping, etc.
Hospitalization may be indicated if the client remains non-
compliant and is a danger to self. If the client is not a danger to
self, and hospitalization is not indicated, the PMHNP needs to
assess for rationale for non-compliance. Many clients enjoy
mania as it is a nice feeling to be consistently happy. When
clients are successfully treated for mania, they often describe
themselves as feeling ‘down’ or ‘flat.’ The PMHNP needs to
assess for depression at this point as opposed to normalization
of mood. Abilify is also FDA approved as monotherapy for
mania and mixed presentations, but at a dose of 15 mg. day., so
although you may be tempted to begin Abilify- be certain to use
correct dose. Also, because it can be “activating” you need to
dose this drug in the morning. However, the client is non-
compliant and therefore, eliciting reasons for non-compliance is
essential to the care of this client.
Start OverChange to abilify 10 mg orally at HS
Guidance to Student
The PMHNP should further assess for
dangerousness to self or others. The client should be assessed
for self-care, to including hygiene, eating, sleeping, etc.
Hospitalization may be indicated if the client remains non-
compliant and is a danger to self. If the client is not a danger to
self, and hospitalization is not indicated, the PMHNP needs to
assess for rationale for non-compliance. Many clients enjoy
mania as it is a nice feeling to be consistently happy. When
clients are successfully treated for mania, they often describe
themselves as feeling ‘down’ or ‘flat.’ The PMHNP needs to
40. assess for depression at this point as opposed to normalization
of mood. Abilify is also FDA approved as monotherapy for
mania and mixed presentations, but at a dose of 15 mg. day., so
although you may be tempted to begin Abilify- be certain to use
correct dose. Also, because it can be “activating” you need to
dose this drug in the morning. However, the client is non-
compliant and therefore, eliciting reasons for non-compliance is
essential to the care of this client.
Start OverAssess rationale for non-compliance to elicit reason
for non-compliance and educate client re: drug effects, and
pharmacology
RESULTS OF DECISION POINT TWO Client returns to clinic
in four weeks Client states that the drug makes her nauseated
and gives her diarrhea Client states that she stops taking it until
these symptoms abate, at which point she re-starts only to
experience the symptoms again
Decision Point Three
Select what the PMHNP should
do next:Change to Depakote ER 500 mg at HS
41. Guidance to Student
In this case, the client is having nausea
and diarrhea, classic side effects of lithium therapy. Changing
the client to an extended release formulation can often prevent
these symptoms while at the same time affording the client the
benefit of lithium’s mood stabilizing properties. Also, lithium is
a good choice for control of mania and has also been shown to
decrease risk of suicide, which adds to its overall benefits.
Depakote may be an option if changing to sustained release
lithium does not alleviate the side effects. Oxcarbazpine
(Trileptal) is an option, but is a second line therapy and is not
appropriate at this stage as the client has not had an adequate
trial of first line agents.
Start OverChange Lithium to sustained release preparation at
same dose and frequency
Guidance to Student
In this case, the client is having nausea
and diarrhea, classic side effects of lithium therapy. Changing
the client to an extended release formulation can often prevent
these symptoms while at the same time affording the client the
benefit of lithium’s mood stabilizing properties. Also, lithium is
a good choice for control of mania and has also been shown to
decrease risk of suicide, which adds to its overall benefits.
Depakote may be an option if changing to sustained release
lithium does not alleviate the side effects. Oxcarbazpine
(Trileptal) is an option, but is a second line therapy and is not
appropriate at this stage as the client has not had an adequate
42. trial of first line agents.
Start OverChange to trileptal 300 mg orally BID
Guidance to Student
In this case, the client is having nausea and
diarrhea, classic side effects of lithium therapy. Changing the
client to an extended release formulation can often prevent
these symptoms while at the same time affording the client the
benefit of lithium’s mood stabilizing properties. Also, lithium is
a good choice for control of mania and has also been shown to
decrease risk of suicide, which adds to its overall benefits.
Depakote may be an option if changing to sustained release
lithium does not alleviate the side effects. Oxcarbazpine
(Trileptal) is an option, but is a second line therapy and is not
appropriate at this stage as the client has not had an adequate
trial of first line agents.
Start OverSwitch to Depakote ER 500 mg orally at HS
RESULTS OF DECISION POINT TWO Client returns to clinic
in four weeks Client reports that she has been compliant and
you notice a marked reduction in manic symptoms. Young
Mania Rating Scale was 11 (50% reduction from first office
visit) Client reports that she has gained 6 pounds over the last 4
43. weeks and wants to stop the medication because of this
Decision Point Three
Select what the PMHNP should
do next:Educate client regarding diet/weight loss and continue
client on the same drug/dose
Guidance to Student
The PMHNP should begin by educating
the client regarding weight loss/and importance of diet/exercise
while taking Depakote which can cause weight gain. Decreasing
the dose of Depakote would not be appropriate as she still has
symptoms and decreasing dose of Depakote may result in some
weight loss, it may result in a return of manic symptoms. The
PMHNP can switch to Zyprexa but if weight gain is the issue,
then this will be compounded by Zyprexa which is associated
with significant weight gain (up to 20 kg over a 24 month
period).
Start OverDecrease Depakote ER to 250 mg orally at HS
Guidance to Student
44. The PMHNP should begin by educating the
client regarding weight loss/and importance of diet/exercise
while taking Depakote which can cause weight gain. Decreasing
the dose of Depakote would not be appropriate as she still has
symptoms and decreasing dose of Depakote may result in some
weight loss, it may result in a return of manic symptoms. The
PMHNP can switch to Zyprexa but if weight gain is the issue,
then this will be compounded by Zyprexa which is associated
with significant weight gain (up to 20 kg over a 24 month
period).
Start OverSwitch medication to Zyprexa 15 mg orally daily at
HS
Guidance to Student
The PMHNP should begin by educating
the client regarding weight loss/and importance of diet/exercise
while taking Depakote which can cause weight gain. Decreasing
the dose of Depakote would not be appropriate as she still has
symptoms and decreasing dose of Depakote may result in some
weight loss, it may result in a return of manic symptoms. The
PMHNP can switch to Zyprexa but if weight gain is the issue,
then this will be compounded by Zyprexa which is associated
with significant weight gain (up to 20 kg over a 24 month
period).
Start Over